SEHK:1345

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

China Pioneer Pharma Holdings

Executive Summary

China Pioneer Pharma Holdings Limited, an investment holding company, markets, promotes, and sells pharmaceutical products and medical devices primarily in the People’s Republic of China. More Details


Snowflake Analysis

Excellent balance sheet and fair value.


Similar Companies

Share Price & News

How has China Pioneer Pharma Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1345 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 1345's weekly volatility has decreased from 19% to 7% over the past year.


Market Performance


7 Day Return

10.6%

1345

-3.3%

HK Healthcare

2.2%

HK Market


1 Year Return

14.3%

1345

-18.2%

HK Healthcare

7.2%

HK Market

Return vs Industry: 1345 exceeded the Hong Kong Healthcare industry which returned -17.9% over the past year.

Return vs Market: 1345 exceeded the Hong Kong Market which returned 7.5% over the past year.


Shareholder returns

1345IndustryMarket
7 Day10.6%-3.3%2.2%
30 Day2.0%-0.2%8.4%
90 Day-1.0%14.9%15.6%
1 Year36.6%14.3%-16.0%-18.2%11.4%7.2%
3 Year-51.4%-59.4%-42.8%-46.4%-3.4%-13.5%
5 Year-22.8%-43.2%-29.9%-32.0%65.4%37.4%

Long-Term Price Volatility Vs. Market

How volatile is China Pioneer Pharma Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is China Pioneer Pharma Holdings undervalued compared to its fair value and its price relative to the market?

26.6%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 1345 (HK$1.04) is trading below our estimate of fair value (HK$1.42)

Significantly Below Fair Value: 1345 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 1345 is poor value based on its PE Ratio (28.7x) compared to the HK Healthcare industry average (20.6x).

PE vs Market: 1345 is poor value based on its PE Ratio (28.7x) compared to the Hong Kong market (11.5x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1345's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1345 is good value based on its PB Ratio (1.1x) compared to the HK Healthcare industry average (1.5x).


Next Steps

Future Growth

How is China Pioneer Pharma Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

25.3%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as China Pioneer Pharma Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has China Pioneer Pharma Holdings performed over the past 5 years?

-19.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1345 has high quality earnings.

Growing Profit Margin: 1345's current net profit margins (2.8%) are lower than last year (4.9%).


Past Earnings Growth Analysis

Earnings Trend: 1345's earnings have declined by 19.7% per year over the past 5 years.

Accelerating Growth: 1345's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 1345 had negative earnings growth (-41.5%) over the past year, making it difficult to compare to the Healthcare industry average (-9.1%).


Return on Equity

High ROE: 1345's Return on Equity (3.8%) is considered low.


Next Steps

Financial Health

How is China Pioneer Pharma Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: 1345's short term assets (CN¥952.8M) exceed its short term liabilities (CN¥281.2M).

Long Term Liabilities: 1345's short term assets (CN¥952.8M) exceed its long term liabilities (CN¥8.0M).


Debt to Equity History and Analysis

Debt Level: 1345's debt to equity ratio (4.6%) is considered satisfactory.

Reducing Debt: 1345's debt to equity ratio has reduced from 78.8% to 4.6% over the past 5 years.

Debt Coverage: 1345's debt is not well covered by operating cash flow (4%).

Interest Coverage: 1345 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is China Pioneer Pharma Holdings's current dividend yield, its reliability and sustainability?

7.36%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 1345's dividend (7.36%) is higher than the bottom 25% of dividend payers in the Hong Kong market (2.13%).

High Dividend: 1345's dividend (7.36%) is in the top 25% of dividend payers in the Hong Kong market (6.66%)


Stability and Growth of Payments

Stable Dividend: 1345 has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: 1345 has only been paying a dividend for 7 years, and since then payments have fallen.


Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (316.8%), 1345's dividend payments are not well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Chunyi Luo (51 yo)

2yrs

Tenure

CN¥869,000

Compensation

Mr. Chunyi Luo has been CEO and Director at China Pioneer Pharma Holdings Ltd since January 22, 2019. He has extensive experience in corporate management and banking. Prior to joining the Group, he had ser...


CEO Compensation Analysis

Compensation vs Market: Chunyi's total compensation ($USD134.11K) is below average for companies of similar size in the Hong Kong market ($USD305.97K).

Compensation vs Earnings: Insufficient data to compare Chunyi's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Xinzhou Li
Executive Chairmanno dataCN¥1.74m2.14%
CN¥ 27.2m
Chunyi Luo
CEO & Executive Director2yrsCN¥869.00kno data
Yi Xue
Chief Financial Officer4.08yrsno datano data
Guoguang Xiao
Executive Director0.83yrno datano data
Ka Man Ng
Company Secretary1.83yrsno datano data
Tao Wang
General Manager of Easyhaler & Neutrophase Business Unit6.33yrsno datano data

2.0yrs

Average Tenure

50yo

Average Age

Experienced Management: 1345's management team is considered experienced (2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Xinzhou Li
Executive Chairmanno dataCN¥1.74m2.14%
CN¥ 27.2m
Chunyi Luo
CEO & Executive Director2yrsCN¥869.00kno data
Guoguang Xiao
Executive Director0.83yrno datano data
Mijia Wu
Non-Executive Director7.25yrsCN¥216.00kno data
Chi Hung Wong
Independent & Non-Executive Director7.25yrsCN¥315.00kno data
Hong Zhang
Independent Non-Executive Director2yrsno datano data
Mingfei Hu
Non-Executive Director0.083yrno datano data
Yongli Wang
Independent Non-Executive Director0.083yrno datano data

2.0yrs

Average Tenure

57yo

Average Age

Experienced Board: 1345's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 1345 insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

China Pioneer Pharma Holdings Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: China Pioneer Pharma Holdings Limited
  • Ticker: 1345
  • Exchange: SEHK
  • Founded: 1996
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: HK$1.271b
  • Shares outstanding: 1.22b
  • Website: https://www.pioneer-pharma.com

Number of Employees


Location

  • China Pioneer Pharma Holdings Limited
  • No.15, Lane 88 Wuwei Road
  • Putuo District
  • Shanghai
  • Shanghai Province
  • 200331
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
1345SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDNov 2013
14PDB (Deutsche Boerse AG)YesOrdinary SharesDEEURNov 2013

Biography

China Pioneer Pharma Holdings Limited, an investment holding company, markets, promotes, and sells pharmaceutical products and medical devices primarily in the People’s Republic of China. It has a portfoli...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/16 10:17
End of Day Share Price2021/01/15 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.